Matussek 210210

 

 

 

 

 

 

Head of Oncology Germany, AstraZeneca

 

Dr. Karl Matussek is Head of Oncology in Germany at AstraZeneca, having joined the company in 2014. He is a trained and PhD graduated biologist. He has spent 17 years with Roche Pharma in Germany in various functions in oncology and hematology.

Matussek is a member of German Association of Hematology and medical Oncology (DGHO), German Cancer Association (DKG) and Working Group Medical Oncology (AIO).

 

Updated: June 2021

 

perettie 210210

 

 

 

 
 
 
 
Head of Roche Molecular Lab

 

Cindy Perettie joined Molecular Diagnostics as the new Head of Molecular Lab Solutions based in Pleasanton, California on April 6, 2021. Prior to that she was at Foundation Medicine starting in February 2019 as its Chief Executive Officer. Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as senior vice president in global oncology product strategy for Roche’s Oncology unit, where she led one of the largest global oncology portfolios in the industry. Ms. Perettie began her tenure at Genentech as a program team leader for bevacizumab, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio, including in lung cancer, breast cancer and hematology. Since joining in 2004, she held roles of increasing responsibility at Genentech, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development.

In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute (SCRI) as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. During her tenure, she was responsible for leading and growing SCRI’s contract research organization globally, driving critical oncology clinical trials to further expand options for cancer patients and access precision medicine. Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation.

She started her career as a senior research associate at Johns Hopkins University following her continuing education program there. Ms. Perettie holds an MBA in marketing and finance from St. Mary’s College of California and received her bachelor’s degree in biology, with a minor in chemistry from State University of New York College at Potsdam.

 

Updated: June 2021

Revel 210210

 

 

 

 
 
 
 
Head of the Radiology department, Cochin Hospital, University of Paris

 

Prof. Revel is currently Head of the Radiology department at Cochin Hospital, University of Paris, Paris, France. Her area of expertise concerns thoracic imaging in particular in the field of thoracic oncology and thromboembolic diseases. She worked on chest imaging applications of artificial intelligence. She is past president of the European Society of Thoracic Imaging (ESTI) and is responsible for the ESTI Lung Cancer Screening certification project, supported by the European Society of Radiology (ESR). She will conduct the CASCADE study, a Lung cancer screening (LCS) implementation study in France, which aims to evaluate the reading modalities of the thoracic CT exams: single reading by a radiologist trained to LCS, role of artificial intelligence.

 

Updated: May 2021

Roobol 210210

 

 

 

 

 
 
Professor, Decision Making in Urology and the Head of the scientific research office within the Department of Urology at Erasmus Medical Centre Rotterdam

 

Monique Roobol is Professor Decision Making in Urology and the Head of the scientific research office within the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a masters and a PhD degree in epidemiology.

The last thirty years have been completely dedicated to research on the early detection of prostate cancer. Next to her significant contribution to the European Randomized study of Screening for Prostate Cancer (ERSPC: www.erspc.org ), she co-developed the “Rotterdam Prostate Cancer Risk calculator: www.prostatecancer-riskcalculator.com), a multi-step risk analysis tools to guide laymen and physician in decision making at diagnosis and the study on active surveillance. (PRIAS: Prostate Cancer Research International Active Surveillance (www.prias-project.org).

The scientific research office performs and supports several clinical and population-based screening studies. On average five PhD students are working under Prof. Roobol’s guidance. She is now the PI of ERSPC and co-PI of PRIAS and the Movember Global Action Plan-3 (active surveillance). Since 2018 she is part of the PIONEER European network for big data in prostate cancer (https://prostate-pioneer.eu/). She is board member of the ERSPC Foundation, and the  chairwoman of the Dutch Prostate Cancer Research Foundation (SWOP).

Prof.  Roobol has (co)-authored over 350 scientific publications, book chapters and reviews. She is an advisory board member of several major trials related to prostate cancer

Prof. Roobol’s research has been awarded with several prices, such as the bi-annual “van Stockum prize” from the Dutch Urological Association for best thesis, the EAU best clinical paper of the year 2009, the European Urology Platinum Award 2011 and 2018 and the BJUI best urological mobile application award 2015.

Her motto is: translate research into useful tools for use within clinical practice:  ”Bridging the gap between epidemiology and urology”  

 

Updated: May 2021